Key Dates

Related Announcements

RFA-AR-21-015 - Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional)

RFA-AR-21-016 - Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

On March 31, 2021, NIH issued the Funding Opportunity Announcements (FOA) RFA-AR-21-015 "Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjögren’s Syndrome (UC2 Clinical Trial Optional)" and RFA-AR-21-016 “Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed)".

Webinar Information

Date: June 7, 2021

Time: 12:00 p.m. to 1:00 p.m. (ET)

Webinar details can be found at: https://www.niams.nih.gov/grants-funding/niams-supported-research-programs/accelerating-medicines-partnership-amp.

Please submit questions in advance for consideration to include in the webinar by June 6, 2021 by 5:00pm (ET) to AMP_AIM@mail.nih.gov. Please note, due to time constraints, questions that are not submitted in advance may not be addressed during the webinar. 

The Pre-Application Webinar will provide information about these FOAs to assist prospective applicants. NIH staff will provide a brief overview of the FOAs and answer questions. The webinar is open to all prospective applicants, but participation in the webinar is not a prerequisite to applying. After the webinar, webinar slides will be posted on the website.

Inquiries

Please direct all inquiries to:

Email: AMP_AIM@mail.nih.gov